<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?</h1>
  <ul>
<li>In 2025, Lilly expects to record revenues in the range of $60.0 billion to $62.0 billion, indicating an impressive year-over-year growth of more than 30% We believe that LLY has solid growth prospects and a promising por</li>
<li>Mounjaro and Zepbound account for around 50% of the company’s total revenues.</li>
<li>Lilly’s stock is up 18% since the second-quarter results, easing some of the recent negative sentiment.</li>
<li>Competition Heating Up in the Obesity Space The obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs, which means fierce competition is inevitable.</li>
<li>In 2025, it announced three M&amp;A deals.</li>
<li>LLY’s Stock Price, Valuation and Estimates Lilly’s stock has declined 2.2% so far this year compared with the industry’s decrease of 0.2%.</li>
<li>In the ATTAIN-2 study in obese adults with type II diabetes, the highest dose (36 mg) of orforglipron delivered a weight loss of up to an average of 22.9 pounds or 10.5%.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/lilly-moves-past-50-day-150800320.html">Source</a> · 2025-09-15T15:08:00+00:00</p>
</body>
</html>